Overexpression of p-MARCKS was associated with unfavorable survival in a series of 195 operated lung cancers and targeting MARCKS phosphorylation site domain (PSD) with MPS peptide (MARCKS phosphorylation site domain) suppressed tumor growth, metastasis and increased the sensibility to erlotinib treatment in vivo and in vitro [27]. Here, MARCKS is linked to neoplasm.